Drug development for liver diseases: focus on picroliv, ellagic acid and curcumin

被引:57
作者
Girish, C. [1 ]
Pradhan, Suresh Chandra [1 ]
机构
[1] JIPMER, Dept Pharmacol, Pondicherry 605006, India
关键词
curcumin; ellagic acid; hepatoprotective; hepatotoxicity; liver disease; picroliv;
D O I
10.1111/j.1472-8206.2008.00618.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The use of herbal drugs for the treatment of liver diseases has a long tradition in many eastern countries. The easy accessibility without the need for laborious pharmaceutical synthesis has drawn increased attention towards herbal medicines. Few herbal preparations exist as standardized extracts with major known ingredients or even as pure compounds. Some of the herbals, which show promising activity, are ellagic acid for antifibrotic treatment, phyllanthin for treating chronic hepatitis B, glycyrrhizin to treat chronic viral hepatitis and picroliv for liver regeneration. These compounds, which have proven antioxidant, antiviral or anticarcinogenic properties, can serve as primary compounds for further development as hepatoprotective drugs. This review provides the chemistry, pharmacology and future aspects of picroliv, ellagic acid and curcumin with focus on hepatoprotective properties. These phytochemicals may prove to be very useful in the treatment of hepatotoxicity induced by viral agents, toxic drugs and plant poisons. The high safety profile may be an added advantage. However, poor bioavailability and temperature and light sensitivity can reduce the efficacy of drugs like curcumin. In future, the derivatives or new combinations of these drugs may prove to be useful.
引用
收藏
页码:623 / 632
页数:10
相关论文
共 85 条
[1]   Drug-induced liver injury [J].
Abboud, Gebran ;
Kaplowitz, Neil .
DRUG SAFETY, 2007, 30 (04) :277-294
[2]  
Aggarwal BB, 2003, ANTICANCER RES, V23, P363
[3]   PHARMACOLOGY OF CURCUMA-LONGA [J].
AMMON, HPT ;
WAHL, MA .
PLANTA MEDICA, 1991, 57 (01) :1-7
[4]  
[Anonymous], 2001, Altern Med Rev, V6, P319
[5]   Biological activities of Curcuma longa L. [J].
Araújo, CAC ;
Leon, LL .
MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2001, 96 (05) :723-728
[6]   Structure-function relationships of the dietary anticarcinogen ellagic acid [J].
Barch, DH ;
Rundhaugen, LM ;
Stoner, GD ;
Pillay, NS ;
Rosche, WA .
CARCINOGENESIS, 1996, 17 (02) :265-269
[7]   Stages of activation of hepatic stellate cells: effects of ellagic acid, an inhibiter of liver fibrosis, on their differentiation in culture [J].
Buniatian, GH .
CELL PROLIFERATION, 2003, 36 (06) :307-319
[8]  
CELA C. J., 1957, PAPELES SONS ARMADAN, V16, P108
[9]   Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats [J].
Chuang, SE ;
Cheng, AL ;
Lin, JK ;
Kuo, ML .
FOOD AND CHEMICAL TOXICOLOGY, 2000, 38 (11) :991-995
[10]  
Clifford MN, 2000, J SCI FOOD AGR, V80, P1118, DOI [10.1002/(SICI)1097-0010(20000515)80:7&lt